Literature DB >> 11437234

Histone acetylation and disease.

S Timmermann1, H Lehrmann, A Polesskaya, A Harel-Bellan.   

Abstract

Differential acetylation of histones and transcription factors plays an important regulatory role in developmental processes, proliferation and differentiation. Aberrant acetylation or deacetylation leads to such diverse disorders as leukemia, epithelial cancers, fragile X syndrome and Rubinstein-Taybi syndrome. The various groups of histone acetyltransferases (CBP/p300, GNAT, MYST, nuclear receptor coactivators and TAFII250) and histone deacetylases are surveyed with regard to their possible or known involvement in cancer progression and human developmental disorders. Current treatment strategies are discussed, which are still mostly limited to histone deacetylase inhibitors such as trichostatin A and butyrate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437234     DOI: 10.1007/pl00000896

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  78 in total

Review 1.  Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics.

Authors:  Anton Eberharter; Peter B Becker
Journal:  EMBO Rep       Date:  2002-03       Impact factor: 8.807

2.  Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study.

Authors:  Patricia L Kramer; Haiyan Xu; Randall L Woltjer; Shawn K Westaway; David Clark; Deniz Erten-Lyons; Jeffrey A Kaye; Kathleen A Welsh-Bohmer; Juan C Troncoso; William R Markesbery; Ronald C Petersen; R Scott Turner; Walter A Kukull; David A Bennett; Douglas Galasko; John C Morris; Jurg Ott
Journal:  Neurobiol Aging       Date:  2010-05-07       Impact factor: 4.673

Review 3.  Regulating histone acetyltransferases and deacetylases.

Authors:  Gaëlle Legube; Didier Trouche
Journal:  EMBO Rep       Date:  2003-10       Impact factor: 8.807

Review 4.  Epigenetic mechanisms in inflammation.

Authors:  D Bayarsaihan
Journal:  J Dent Res       Date:  2011-01       Impact factor: 6.116

5.  Schizosaccharomyces pombe mst2+ encodes a MYST family histone acetyltransferase that negatively regulates telomere silencing.

Authors:  Eliana B Gómez; Joaquín M Espinosa; Susan L Forsburg
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

6.  Anti-Epileptic Drug Targets Ewing Sarcoma.

Authors:  Shubhalaxmi Kayarthodi; Yasuo Fujimura; Jinbo Fang; Sharif Morsalin; Veena N Rao; E Shyam P Reddy
Journal:  J Pharm Sci Pharmacol       Date:  2014-06-01

7.  Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.

Authors:  Shashirekha Shetty; Bonnie A Graham; Jennifer G Brown; Xiaojie Hu; Nicolette Vegh-Yarema; Gary Harding; James T Paul; Spencer B Gibson
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

8.  Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.

Authors:  Sanjib Chowdhury; Gillian M Howell; Carol A Teggart; Aparajita Chowdhury; Jonathan J Person; Dawn M Bowers; Michael G Brattain
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

9.  Suppression of lipopolysaccharide- and tumour necrosis factor-alpha-induced interleukin (IL)-8 expression by glucocorticoids involves changes in IL-8 promoter acetylation.

Authors:  L G Tsaprouni; K Ito; I M Adcock; N Punchard
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

10.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors:  Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.